Cogent Biosciences COGT
NASDAQ COGT
$29.81 -1.83 (-5.78%)
As of: Nov 11, 2026 · 11:46 AM EST

Cogent Biosciences (COGT) Debt Ratio (2025)

Updated

Cogent Biosciences' Debt Ratio came in at 0.10 for Q3 2025, down 35.0% from the prior quarter.

Analysis

Cogent Biosciences (COGT) Debt Ratio (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 0.33
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 0.23
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 0.55
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 0.41
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -0.06
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 0.56
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 0.51
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 0.31
10 Cogent Biosciences 5.50 Bn 2.15 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 0.10
Jun 30, 2025 0.16
API Access

Cogent Biosciences Debt Ratio API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=debt-ratio&ticker=COGT&period=max&api_key=YOUR_API_KEY